Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T22977
(Former ID: TTDR00265)
|
|||||
| Target Name |
Superoxide dismutase Cu-Zn (SOD Cu-Zn)
|
|||||
| Synonyms |
hSod1; Superoxide dismutase [Cu-Zn]; Superoxide dismutase 1; Superoxide dismutase
|
|||||
| Gene Name |
SOD1
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 2 Target-related Diseases | + | ||||
| 1 | Dissociative neurological symptom disorder [ICD-11: 6B60] | |||||
| 2 | Motor neuron disease [ICD-11: 8B60] | |||||
| Function |
Destroys radicals which are normally produced within the cells and which are toxic to biological systems.
Click to Show/Hide
|
|||||
| BioChemical Class |
Superoxide dismutase/reductase
|
|||||
| UniProt ID | ||||||
| EC Number |
EC 1.15.1.1
|
|||||
| Sequence |
MATKAVCVLKGDGPVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHEFGDNTAGCTS
AGPHFNPLSRKHGGPKDEERHVGDLGNVTADKDGVADVSIEDSVISLSGDHCIIGRTLVV HEKADDLGKGGNEESTKTGNAGSRLACGVIGIAQ Click to Show/Hide
|
|||||
| 3D Structure | Click to Show 3D Structure of This Target | PDB | ||||
| ADReCS ID | BADD_A03234 ; BADD_A03633 ; BADD_A04153 ; BADD_A04623 ; BADD_A06020 | |||||
| HIT2.0 ID | T30D9G | |||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 9 Clinical Trial Drugs | + | ||||
| 1 | BIIB067 | Drug Info | Phase 3 | Amyotrophic lateral sclerosis | [2] | |
| 2 | Coprexa | Drug Info | Phase 3 | Neurological disorder | [1] | |
| 3 | ATN-224 | Drug Info | Phase 2 | Solid tumour/cancer | [3] | |
| 4 | Midismase | Drug Info | Phase 2 | Cerebral infarction | [4] | |
| 5 | PC-SOD | Drug Info | Phase 2 | Interstitial lung disease | [5] | |
| 6 | Superoxide dismutase | Drug Info | Phase 2 | Myocardial infarction | [6] | |
| 7 | Tempol | Drug Info | Phase 2 | Spinal cord injury | [7] | |
| 8 | APN-201 | Drug Info | Phase 1/2 | Dermatitis | [8] | |
| 9 | EUK-189 | Drug Info | Phase 1 | Skin burns | [9] | |
| Preclinical Drug(s) | [+] 1 Preclinical Drugs | + | ||||
| 1 | AEOL-10150 | Drug Info | Preclinical | Multiple sclerosis | [10] | |
| Discontinued Drug(s) | [+] 3 Discontinued Drugs | + | ||||
| 1 | EUK-207 | Drug Info | Terminated | Neurodegenerative disorder | [11] | |
| 2 | M-40401 | Drug Info | Terminated | Cerebrovascular ischaemia | [12] | |
| 3 | Pegorgotein | Drug Info | Terminated | Head injury | [13] | |
| Mode of Action | [+] 2 Modes of Action | + | ||||
| Inhibitor | [+] 6 Inhibitor drugs | + | ||||
| 1 | BIIB067 | Drug Info | [14] | |||
| 2 | Coprexa | Drug Info | [1] | |||
| 3 | ATN-224 | Drug Info | [1] | |||
| 4 | Methoxyestradiol | Drug Info | [15] | |||
| 5 | Acetate Ion | Drug Info | [24] | |||
| 6 | TDI-0107 | Drug Info | [1] | |||
| Modulator | [+] 14 Modulator drugs | + | ||||
| 1 | Midismase | Drug Info | [16] | |||
| 2 | PC-SOD | Drug Info | [16] | |||
| 3 | Superoxide dismutase | Drug Info | [17] | |||
| 4 | Tempol | Drug Info | [18], [19] | |||
| 5 | APN-201 | Drug Info | [20] | |||
| 6 | EUK-189 | Drug Info | [9] | |||
| 7 | AEOL-10150 | Drug Info | [21] | |||
| 8 | EUK-207 | Drug Info | [11] | |||
| 9 | M-40401 | Drug Info | [22] | |||
| 10 | Pegorgotein | Drug Info | [23] | |||
| 11 | EC-SOD | Drug Info | [25] | |||
| 12 | TDI-0060 | Drug Info | [1] | |||
| 13 | TDI-0079 | Drug Info | [1] | |||
| 14 | VLTS-582 | Drug Info | [26] | |||
| Chemical Structure based Activity Landscape of Target | Top |
|---|---|
| Drug Property Profile of Target | Top | |
|---|---|---|
| (1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
|
||
| (3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
|
||
| (5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
|
||
| "RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five | ||
| Target Poor or Non Binders | Top | |||||
|---|---|---|---|---|---|---|
| Target Poor or Non Binders | ||||||
| Target Regulators | Top | |||||
|---|---|---|---|---|---|---|
| Target-regulating microRNAs | ||||||
| Target-regulating Transcription Factors | ||||||
| Target-interacting Proteins | ||||||
| Target Profiles in Patients | Top | |||||
|---|---|---|---|---|---|---|
| Target Expression Profile (TEP) | ||||||
| Target Affiliated Biological Pathways | Top | |||||
|---|---|---|---|---|---|---|
| BioCyc | [+] 1 BioCyc Pathways | + | ||||
| 1 | Reactive oxygen species degradation | |||||
| KEGG Pathway | [+] 4 KEGG Pathways | + | ||||
| 1 | Peroxisome | |||||
| 2 | Amyotrophic lateral sclerosis (ALS) | |||||
| 3 | Huntington's disease | |||||
| 4 | Prion diseases | |||||
| NetPath Pathway | [+] 1 NetPath Pathways | + | ||||
| 1 | TCR Signaling Pathway | |||||
| Pathwhiz Pathway | [+] 1 Pathwhiz Pathways | + | ||||
| 1 | Degradation of Superoxides | |||||
| PID Pathway | [+] 2 PID Pathways | + | ||||
| 1 | Validated nuclear estrogen receptor alpha network | |||||
| 2 | FOXA1 transcription factor network | |||||
| Reactome | [+] 2 Reactome Pathways | + | ||||
| 1 | Platelet degranulation | |||||
| 2 | Detoxification of Reactive Oxygen Species | |||||
| WikiPathways | [+] 10 WikiPathways | + | ||||
| 1 | Oxidative Stress | |||||
| 2 | Copper homeostasis | |||||
| 3 | Detoxification of Reactive Oxygen Species | |||||
| 4 | Nifedipine Activity | |||||
| 5 | Amyotrophic lateral sclerosis (ALS) | |||||
| 6 | Dopamine metabolism | |||||
| 7 | AGE/RAGE pathway | |||||
| 8 | Folate Metabolism | |||||
| 9 | Vitamin B12 Metabolism | |||||
| 10 | Selenium Micronutrient Network | |||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82. | |||||
| REF 2 | ClinicalTrials.gov (NCT04856982) A Study of BIIB067 When Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation (ATLAS). U.S. National Institutes of Health. | |||||
| REF 3 | ClinicalTrials.gov (NCT00405574) Study of ATN-224 in Patients With Prostate Cancer. U.S. National Institutes of Health. | |||||
| REF 4 | ClinicalTrials.gov (NCT00685763) Proton Therapy for Unresectable Cancer (CA) of Pancreas. U.S. National Institutes of Health. | |||||
| REF 5 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032052) | |||||
| REF 6 | Phase II trial of copper zinc superoxide dismutase (CuZn SOD) in the treatment of Crohn's disease. Free Radic Res Commun. 1991;12-13 Pt 2:563-9. | |||||
| REF 7 | ClinicalTrials.gov (NCT00801086) Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain. U.S. National Institutes of Health. | |||||
| REF 8 | ClinicalTrials.gov (NCT01513278) Study of APN201 (Liposomal Recombinant Human Cu/Zn-Superoxide Dismutase) for the Prevention of Radiation-induced Dermatitis in Women With Breast Cancer. U.S. NationalInstitutes of Health. | |||||
| REF 9 | Evaluation of EUK-189, a synthetic superoxide dismutase/catalase mimetic as a radiation countermeasure. Immunopharmacol Immunotoxicol. 2008;30(2):271-90. | |||||
| REF 10 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013050) | |||||
| REF 11 | A synthetic superoxide dismutase/catalase mimetic EUK-207 mitigates radiation dermatitis and promotes wound healing in irradiated rat skin. J Invest Dermatol. 2013 Apr;133(4):1088-96. | |||||
| REF 12 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018067) | |||||
| REF 13 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005631) | |||||
| REF 14 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 15 | Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol. A superoxide dismutase inhibitor. J Biol Chem. 2003 Jan 3;278(1):407-14. | |||||
| REF 16 | A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis | |||||
| REF 17 | Polyhemoglobin-superoxide dismutase-catalase-carbonic anhydrase: a novel biotechnology-based blood substitute that transports both oxygen and carbon dioxide and also acts as an antioxidant.Artif Cells Blood Substit Immobil Biotechnol.2011 Jun;39(3):127-36. | |||||
| REF 18 | The superoxide dismutase mimetic, tempol, reduces the bioavailability of nitric oxide and does not alter L-NAME-induced hypertension in rats. Basic Clin Pharmacol Toxicol. 2005 Jul;97(1):29-34. | |||||
| REF 19 | Effect of the addition of two superoxide dismutase analogues (Tempo and Tempol) to alpaca semen extender for cryopreservation. Theriogenology. 2013 Mar 15;79(5):842-6. | |||||
| REF 20 | Peyronie's disease: a critical appraisal of current diagnosis and treatment. Int J Impot Res. 2008 Sep-Oct;20(5):445-59. | |||||
| REF 21 | AEOL-10150 (Aeolus). Curr Opin Investig Drugs. 2006 Jan;7(1):70-80. | |||||
| REF 22 | Protective effects of a new stable, highly active SOD mimetic, M40401 in splanchnic artery occlusion and reperfusion. Br J Pharmacol. 2001 Jan;132(1):19-29. | |||||
| REF 23 | Clinical trials with Dismutec (pegorgotein; polyethylene glycol-conjugated superoxide dismutase; PEG-SOD) in the treatment of severe closed head injury. Adv Exp Med Biol. 1994;366:389-400. | |||||
| REF 24 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||||
| REF 25 | Extracellular superoxide dismutase (ecSOD) in vascular biology: an update on exogenous gene transfer and endogenous regulators of ecSOD.Transl Res.2008 Feb;151(2):68-78. | |||||
| REF 26 | A Phase I Study of Concurrent Chemotherapy (Paclitaxel and Carboplatin) and Thoracic Radiotherapy with Swallowed Manganese Superoxide Dismutase Plasmid Liposome Protection in Patients with Locally Advanced Stage III Non-Small-Cell Lung Cancer | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.